News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
692,556 Results
Type
Article (39382)
Company Profile (247)
Press Release (652927)
Section
Business (204037)
Career Advice (2005)
Deals (35407)
Drug Delivery (93)
Drug Development (80946)
Employer Resources (169)
FDA (16134)
Job Trends (14830)
News (344896)
Policy (32475)
Tag
Academia (2535)
Alliances (49315)
Alzheimer's disease (1314)
Approvals (16118)
Artificial intelligence (199)
Bankruptcy (357)
Best Places to Work (11638)
Biotechnology (175)
Breast cancer (225)
Cancer (1710)
Cardiovascular disease (128)
Career advice (1669)
CAR-T (121)
Cell therapy (353)
Clinical research (65248)
Collaboration (659)
Compensation (370)
COVID-19 (2564)
C-suite (160)
Data (1629)
Diabetes (211)
Diagnostics (6282)
Earnings (85439)
Employer resources (146)
Events (110866)
Executive appointments (564)
FDA (17035)
Funding (602)
Gene therapy (245)
GLP-1 (648)
Government (4357)
Healthcare (18767)
Infectious disease (2675)
Interviews (310)
IPO (16460)
Job creations (3628)
Job search strategy (1420)
Layoffs (437)
Legal (7887)
Lung cancer (255)
Manufacturing (235)
Medical device (13261)
Medtech (13266)
Mergers & acquisitions (19322)
Metabolic disorders (548)
Neuroscience (1715)
NextGen: Class of 2025 (6509)
Non-profit (4475)
Northern California (2090)
Obesity (306)
Opinion (193)
Patents (162)
People (56832)
Phase I (20315)
Phase II (28745)
Phase III (21401)
Pipeline (711)
Postmarket research (2562)
Preclinical (8575)
Radiopharmaceuticals (241)
Rare diseases (321)
Real estate (5898)
Regulatory (21917)
Research institute (2311)
Resumes & cover letters (349)
Southern California (1791)
Startups (3568)
United States (18436)
Vaccines (611)
Weight loss (208)
Date
Today (11)
Last 7 days (593)
Last 30 days (2481)
Last 365 days (34397)
2025 (4427)
2024 (35217)
2023 (40076)
2022 (51173)
2021 (55711)
2020 (54083)
2019 (46539)
2018 (35018)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31323)
2013 (26353)
2012 (28572)
2011 (29265)
2010 (27332)
Location
Africa (716)
Arizona (211)
Asia (37506)
Australia (6132)
California (4761)
Canada (1715)
China (392)
Colorado (217)
Connecticut (230)
Europe (80406)
Florida (688)
Georgia (165)
Illinois (455)
Indiana (259)
Japan (121)
Maryland (739)
Massachusetts (3602)
Michigan (198)
Minnesota (334)
New Jersey (1347)
New York (1359)
North Carolina (833)
Northern California (2090)
Ohio (173)
Pennsylvania (1098)
South America (1093)
Southern California (1791)
Texas (701)
Utah (143)
Washington State (467)
692,556 Results for "neurelis inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
NEURELIS PRESENTS STUDIES ON SEIZURE CLUSTERS AT THE AMERICAN EPILEPSY SOCIETY ANNUAL MEETING
December 9, 2024
·
11 min read
Biotech Beach
NEURELIS ANNOUNCES TWO POSTER PRESENTATIONS AT THE 76TH ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY
Neurelis, Inc. will present a poster on VALTOCO® (diazepam nasal spray) for the treatment of episodes of frequent seizure activity (i.e., seizure clusters) in patients with epilepsy ages 6 to 65 years, describing the time to treatment across different subpopulations.
April 11, 2024
·
8 min read
Biotech Beach
Neurelis, Inc. to Participate in the 6th Annual Evercore ISI HealthCONx Conference
Neurelis, Inc., a company focused on epilepsy and orphan neurologic disorders, today announced that corporate leadership will participate in and host one-on-one investor meetings at the 6th Annual Evercore ISI HealthCONx Conference, to be held in Miami from November 28-30, 2023.
November 16, 2023
·
1 min read
Biotech Beach
Neurelis to Host Virtual Pipeline Update to Discuss Advancements Addressing Unmet Needs in Neuroscience on March 7, 2024
Neurelis, Inc., today announced it will host an investor call to highlight updates on two of its neuroscience product development candidates, The investor call will be held virtually on Thursday, March 7, 2024 at 10:30 AM ET.
February 26, 2024
·
6 min read
Biotech Beach
NEURELIS ANNOUNCES PRESENTATIONS AT THE AMERICAN EPILEPSY SOCIETY ANNUAL MEETING
Neurelis, Inc., today announced that the company will present six poster presentations at the American Epilepsy Society (AES) Annual Meeting held in Orlando, Florida from December 1 – 5, 2023.
December 1, 2023
·
11 min read
Press Releases
NEURELIS TO SHARE CLINICAL STUDY DESIGN INSIGHTS FOR INVESTIGATION OF VALTOCO® (DIAZEPAM NASAL SPRAY) IN AGES 2 TO 5 AT CHILD NEUROLOGY SOCIETY ANNUAL MEETING
November 12, 2024
·
6 min read
Biotech Beach
NEURELIS SECURES NEW ORANGE BOOK LISTED U.S. PATENT FOR VALTOCO® (DIAZEPAM NASAL SPRAY) CIV
Neurelis, Inc., a neuroscience company focused on the development and commercialization of therapeutics for the treatment of epilepsy and orphan neurologic disorders characterized by high unmet medical need, announced that it has secured the issuance of United States Patent No. 11,793,786 (the ‘786 Patent).
November 27, 2023
·
7 min read
Biotech Beach
NEURELIS TO PARTICIPATE IN 11th ANNUAL SOFIE’S JOURNEY EPILEPSY AWARENESS DAY AND EDUCATION EXPO AT DISNEYLAND® RESORT
Neurelis Inc., is proud to take part in the 11th Annual Sofie’s Journey Epilepsy Awareness Day and Education Expo at Disneyland Resort (EADDL), the largest, worldwide epilepsy community gathering of the year.
October 30, 2023
·
9 min read
Drug Development
NEURELIS TO PRESENT ANALYSES OF VALTOCO® (diazepam nasal spray) CIV AT THE 52nd CHILD NEUROLOGY SOCIETY ANNUAL MEETING
Neurelis, Inc., today announced additional findings from the post hoc analysis of the long-term phase 3 safety study of VALTOCO® (diazepam nasal spray) in a pediatric population, aged 6-17 years, as well as an analysis of real-world data on impact of administration of rescue medication on seizure timing.
October 4, 2023
·
9 min read
Press Releases
NeurAxis Inc. to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
January 6, 2025
·
3 min read
1 of 69,256
Next
